Cameron Shaw - Virax Biolabs COO Director
| VRAX Stock | USD 2.07 0.05 2.48% |
Insider
Cameron Shaw is COO Director of Virax Biolabs Group
| Age | 37 |
| Address | BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH |
| Phone | 44 20 7788 7414 |
| Web | https://viraxbiolabs.com |
Virax Biolabs Management Efficiency
The company has return on total asset (ROA) of (0.499) % which means that it has lost $0.499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9598) %, meaning that it created substantial loss on money invested by shareholders. Virax Biolabs' management efficiency ratios could be used to measure how well Virax Biolabs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.16 in 2024. At this time, Virax Biolabs' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.2 M in 2024, whereas Total Assets are likely to drop slightly above 3.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Joan Brown | Allarity Therapeutics | 70 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| James Rolke | Revelation Biosciences | 55 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Frank Kondrad | Neurobo Pharmaceuticals | N/A | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| James JD | Allarity Therapeutics | 55 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Chester III | Revelation Biosciences | 44 | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| John CPA | Unicycive Therapeutics | 62 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.5 |
Virax Biolabs Group Leadership Team
Elected by the shareholders, the Virax Biolabs' board of directors comprises two types of representatives: Virax Biolabs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virax. The board's role is to monitor Virax Biolabs' management team and ensure that shareholders' interests are well served. Virax Biolabs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virax Biolabs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tomasz George, Chief Officer | ||
| Joel Yeung, Accounting Manager | ||
| Nigel MSc, Chief Officer | ||
| Cameron Shaw, COO Director | ||
| James Wang, Head Sourcing | ||
| James Foster, Chairman CEO | ||
| Mark Ternouth, Chief Director | ||
| Jason Davis, Chief Officer | ||
| Lily Fu, Head Chain | ||
| Clement Monteil, Head Development |
Virax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virax Biolabs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (42.54) % | ||||
| Current Valuation | 2.08 M | ||||
| Shares Outstanding | 4.34 M | ||||
| Shares Owned By Insiders | 7.06 % | ||||
| Shares Owned By Institutions | 5.37 % | ||||
| Number Of Shares Shorted | 284.03 K | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 57.46 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.